Bill Analyses and Ratings

Bill Summary

House Bill 497 comprehensively updates Idaho’s Uniform Controlled Substances Act by revising all five drug schedules to reflect the current landscape of synthetic opioids, designer drugs, and other controlled substances. Schedule I additions include numerous fentanyl analogs (beta-methylacetyl fentanyl, meta-fluorofuranyl fentanyl, ortho-chlorofentanyl, para-chlorofentanyl, tetrahydrothiofuranyl fentanyl), nitazene-class opioids (N-desethyl isotonitazene, N-piperidinyl etonitazene), the designer benzodiazepine bromazolam, and the stimulant ethylphenidate. The bill also expands the definition of fentanyl-related substances to include substitution on the aniline ring, broadening the catch-all provision for novel fentanyl analogs not yet specifically named.

Beyond scheduling changes, the bill restructures several administrative provisions. Controlled substance registrations shift from annual to biennial renewal. Norfentanyl is reclassified from a standalone Schedule II opiate to a listed immediate precursor to fentanyl. Tapentadol moves within Schedule II from the vegetable/synthetic substances subsection to the opiates subsection. Serdexmethylpheniate is reclassified within Schedule IV from depressants to stimulants, and brexanolone moves from Schedule IV’s ‘other substances’ category to the depressants list. Several opioid antagonists—naldemedine, naloxegol, 6β-naltrexol, and samidorphan—are added to the exclusion list for Schedule II opium derivatives, meaning they are not treated as controlled substances.

The bill also tightens enforcement and database provisions. When a registrant’s controlled substance registration is revoked, substances under seal ‘shall’ (previously ‘may’) be forfeited to the state for transfer to a reverse distributor. The controlled substances prescriptions database section is reorganized to consolidate three separate misdemeanor offenses—misrepresentation to obtain access, unauthorized disclosure of patient data, and reckless sharing of login credentials—into a single unified provision. The definition of ‘delegate’ for database access is broadened from specific job titles to ‘health care staff’ and ‘current health profession student,’ and the registration requirement for database access is moved from the database statute into the registration requirements statute, now explicitly covering dispensers as well as prescribers.

Overall Assessment

This bill’s most significant real-world impact is the addition of dozens of newly identified synthetic opioids and fentanyl analogs to Schedule I, directly targeting the evolving illicit drug supply responsible for overdose deaths in Idaho. Law enforcement and prosecutors gain clearer statutory authority to charge offenses involving these substances, while the mandatory forfeiture provision ensures that controlled substances seized from revoked registrants are removed from circulation rather than left to administrative discretion. Healthcare providers benefit from biennial rather than annual registration renewal and from the exclusion of several opioid antagonist medications from Schedule II classification, reducing regulatory friction around overdose-reversal and addiction treatment drugs.